Kyntra Bio (NASDAQ:KYNB) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Kyntra Bio (NASDAQ:KYNB) from a hold rating to a sell rating in a research report report published on Saturday.

KYNB has been the topic of a number of other reports. HC Wainwright raised shares of Kyntra Bio to a “strong-buy” rating in a report on Friday, February 27th. Zacks Research cut Kyntra Bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Finally, Weiss Ratings assumed coverage on Kyntra Bio in a research report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kyntra Bio has a consensus rating of “Hold”.

Kyntra Bio Price Performance

NASDAQ KYNB opened at $7.06 on Friday. The company has a market capitalization of $28.59 million, a price-to-earnings ratio of 0.16 and a beta of 0.84. The stock’s fifty day moving average price is $7.73. Kyntra Bio has a 1 year low of $4.85 and a 1 year high of $12.60.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.